These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23150219)

  • 1. CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families.
    Fachal L; Santamariña M; Blanco A; Carracedo A; Vega A
    Clin Transl Oncol; 2013 Feb; 15(2):164-5. PubMed ID: 23150219
    [No Abstract]   [Full Text] [Related]  

  • 2. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
    Choi DH; Cho DY; Lee MH; Park HS; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2008 Dec; 112(3):569-73. PubMed ID: 18175216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHEK2:1100delC and female breast cancer in the United States.
    Mateus Pereira LH; Sigurdson AJ; Doody MM; Pineda MA; Alexander BH; Greene MH; Struewing JP
    Int J Cancer; 2004 Nov; 112(3):541-3. PubMed ID: 15382084
    [No Abstract]   [Full Text] [Related]  

  • 5. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of CHEK2 mutations in Spanish families with hereditary breast cancer.
    Bellosillo B; Tusquets I; Longarón R; Pérez-Lezaun A; Bellet M; Fabregat X; Serrano S; Solé F
    Cancer Genet Cytogenet; 2005 Aug; 161(1):93-5. PubMed ID: 16080966
    [No Abstract]   [Full Text] [Related]  

  • 9. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
    Rajkumar T; Soumittra N; Nancy NK; Swaminathan R; Sridevi V; Shanta V
    Asian Pac J Cancer Prev; 2003; 4(3):203-8. PubMed ID: 14507240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHEK2 1100delC is not a risk factor for male breast cancer population.
    Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
    Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
    Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
    Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug; 23(4):443-5. PubMed ID: 16883537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited relevance of the CHEK2 gene in hereditary breast cancer.
    Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
    Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?
    Gutiérrez-Enríquez S; Balmaña J; Baiget M; Díez O
    Breast Cancer Res Treat; 2008 Feb; 107(3):455-7. PubMed ID: 17458694
    [No Abstract]   [Full Text] [Related]  

  • 17. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families.
    Sánchez de Abajo A; de la Hoya M; Godino J; Furió V; Tosar A; Pérez-Segura P; Díaz-Rubio E; Caldés T
    Fam Cancer; 2005; 4(2):183-6. PubMed ID: 15951971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families.
    Abud J; Koehler-Santos P; Ashton-Prolla P; Prolla JC;
    Arq Gastroenterol; 2012 Dec; 49(4):273-8. PubMed ID: 23329222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.